Didemnins, a new class of depsipeptides isolated from a Caribbean tunicate, have been shown to have potent antiviral activity against a broad range of RNA viruses in vitro. Didemnins A and B both protected mice against a lethal challenge of Rift Valley fever virus.
Systematic studies of marine natural products overlay medium (basal medium Eagle with Earle have revealed a number of compounds with salts and 16 mM HEPES, 7.5% [vol/vol] heatantibacterial, antifungal, and antiviral activity inactivated fetal bovine serum, 0.25% (wt/vol] (3). Of current interest are the didemnins, a new agarose, 5 gPg of gentamicin per ml) was added class of depsipeptides isolated from a Caribbean per well, and the cells were further incubated at tunicate (ascidian, sea squirt), which inhibit a 37*C for the time required to yield optimal number of DNA and RNA viruses (1,2). Didemplaque formation for each virus. Tissue culture nins A and B were shown to inhibit the in vitro plates were then stained, PFU were counted, growth of herpes simplex virus types 1 and 2 at and tissue culture toxicity was assessed microconcentrations of 1.0 and 0.05 gAM, respectively.
scopically on the basis of cytopathic effects. Similar efficacy was demonstrated against three Didemnins A and B were both found to exhibit RNA viruses (coxsackievirus A21, equine rhino-significant activity against RVF (median inhibivirus, and parainfluenza virus 3). We now report tion dose [ID5o] for didemnins A and B was 1.37 results of studies demonstrating the efficacy of and 0.04 gg/ml, respectively), Venezuelan the two didemnins against a number of RNA equine encephalomyelitis virus (IDo, 0.43 and viruses representing families containing highly 0.08 gag/ml, respectively), and yellow fever virus virulent human pathogens for which no effective (IDse, 0.4 and 0.08 pg/ml, respectively). A contherapy or prophylaxis presently exists. We centration of 0.1 Pgg of didemnin B per ml show here the first example of in vivo protection inhibited plaque formation by these three virusby the didemnins against a lethal challenge with es by more than 80%. Didemnin A, on the other Rift Valley fever virus (RVF).
hand, was less efficient, requiring a 25-fold inThe antiviral activity of didemnins A and B crease in concentration to achieve the same was studied in vitro with a plaque reduction level of virus plaque inhibition. Both didemnins assay on Vero-76 cells (CRL1587) for RVF A and B showed mild cytotoxicity in Vero-76 4 (Zagazig 501), Venezuelan equine encephalomy-cells as judged by phase-contrast microscopy at elitis virus (Trinidad donkey), and Pichinde vi-concentrations greater than 5 and 0.5 pga/ml (5.3 rus AN 3739 and on LLC-MK 2 cells (CCL?) for and 0.45 M), respectively, consisting of inyellow fever virus (Asibi). Didemnins A and B creased vacuolation with moderate cell rounding were dissolved in ethanol, reconstituted with but no detachment. As compared with the other Hanks balanced salt solution, and buffered to three test viruses, Pichinde virus (ID0 for dipH 7.2 with 10amM HEPES (N-2-hydroxyethyl-demnins A and B was 2.9 and 0.22 p4/mI, >-piperazine-N'-2-ethanesulfonic acid) plus 2% respectively), a representative arenavirus, was 6 (vol/vol) heat-inactivated fetal bovine serum (4% less sensitive to the in vitro antiviral effect of • ethanol, final concentration). Drug solutions (0.3 both didemnins.
Sml) of appropriate concentration (0 to 2.5 P4Iml
Studies were also conducted with RVF-infectfor didemnin A and 0 to 0.5 p/mi for didemnin ed mice. Female Swiss Webster mice, 3 to 4 -',j 3) were added to 24-well tissue culture trays weeks of age, were cha'lenged subcutaneously ,j(Falcon). Virs (0.1 ad, 50 to 200 PFU) or with approximately 2M PFU of RVF per 0.1 ad. medium (for tissue culture toxicity controls) was Drugs in ethanol (IP% final concentration), disw then added. After incubating the trays for 40 min solved in phosphatebufered sodium chloride ,.2 to allow adsorption of the virus, 0.5 ml of (0.15 M, pH 7.2), were administered subcutane-01 06 Didemnins, dissolved in ethanol and reconstituted with Hanks balanced salt solution buffered to pH 7.2 with 10 aM HEPES (4% ethanol, final concentration), were given daily beginning on day -1 for 5 consecutive days.
Ten mice per group, inoculated subcutaneously with 250 to 350 PFU of RVF.
ously for 5 days starting 1 day before virus chemical modification. If the antiviral action of inoculation. Treatment with didemnin A at a the didemnins proves to be mediated by a differdose of 1.25 to 5 mg/kg per day resulted in 50% ent mechanism(s) than that which causes their survival for mice challenged with RVF ( Table 1) . toxic effects, then it should be possible to manipHigher dosages given to inoculated but not to ulate the chemical structure of the didemnins so control mice appeared to be toxic. Treatment of as to reduce their toxic properties and yet retain RVF-infected mice with didemnin B (0.25 ma/kg their antiviral activity. Although the therapeutic per day) resulted in a 90% survival ratL, al-index of the current derivatives is low, the though some drug-related deaths were observed. didemnins may yet prove to be important either There were no drug-related deaths when the alone or in combination with other antiviral dose was lowered to 0.20 mg/kg, although at this agents for the treatment of highly lethal viral dose the survival rate was decreased to 40%. infections. Didemnin B was toxic and uniformly lethal to mice when administered at 1.0 mg/kg per day for pounds offers a number of opportunities for U79-h17.
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